RxDoctor Payments Data

Rachel Bender Ignacio, MD

Infectious Disease · Seattle, WANPI 1659532885

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $8,552 of the $8,604 with a category attached, or 99.4%. AbbVie accounts for 71.5% of it on its own, with 2 other manufacturers making up the rest.

$8,604in general payments, 2019–2025

Across 8 payments — averaging $1075.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$6K
  • Seagen Inc.$2K
  • Gilead$52
$819,989in research payments, 2019–2025

Across 10 payments — averaging $81,999 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Viiv Healthcare Company$445K
  • Novartis$375K

What the payments were for

  • Consulting fees$8,55299%
  • Food & beverage$521%

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie5$6,152
Seagen Inc.1$2,400
Gilead2$52

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,604 in reported general payments places this provider in the 85th percentile of 186 infectious disease providers in Washington.

See all infectious disease providers in Washington

Medicare billing

Part B allowed, 2024
$8,027
Medicare patients
27
Services billed
63

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TivicayDolutegravir Sodium89$208,299
DescovyEmtricitabine/Tenofov Alafenam71$156,146
BiktarvyBictegrav/Emtricit/Tenofov Ala38$153,576
TriumeqAbacavir/Dolutegravir/Lamivudi38$115,785
JulucaDolutegravir/Rilpivirine24$78,783
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf12$52,863
DovatoDolutegravir Sodium/Lamivudine12$34,831
SuboxoneBuprenorphine Hcl/Naloxone Hcl24$9,413
JardianceEmpagliflozin12$6,862
JanuviaSitagliptin Phosphate13$6,159
Ampicillin Sodium11$4,283
VascepaIcosapent Ethyl13$2,673
ValacyclovirValacyclovir Hcl39$2,140
Aripiprazole20$1,545
Atorvastatin Calcium59$664

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadDescovy, Biktarvy$52$309,721109 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 186 infectious disease providers in Washington.

Other infectious disease in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →